ArticleBiomaterials advances2026
Janus bilayer coating of functional quaternized chitosan and borate bioactive glass for antibacterial protection and osseointegration.
Article in Biomaterials advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Peri-implant infection and insufficient osseointegration remain leading causes of implant failure, yet existing surface strategies address these challenges sequentially rather than concurrently. A hierarchically organized bilayer coating was developed on titanium by integrating an electrospun quaternized chitosan and poly(vinyl alcohol) nanofibrous base with an electrosprayed overlayer of borate bioactive glass nanospheres encapsulated within a quaternized chitosan shell. The Si-free ternary 70B₂O₃-25CaO-5K₂O composition, synthesized via a surfactant-directed sol-gel route, yields monodisperse spherical nanoparticles; shell encapsulation reduces cumulative boron release to 78.2% over 14 days and suppresses burst release to 0.33% at 2 h, sustaining ion delivery within the cytocompatible and osteogenically active range. Broad-spectrum bactericidal activity against a clinically representative polymicrobial peri-implant panel was achieved through synergistic contact killing and borate dissolution derived ionic perturbation. Among formulations evaluated, B40 comprising 40 wt% quaternized chitosan and 5 wt% bioactive glass simultaneously maximized infection control and osteogenic maturation in primary human mesenchymal stem cells, producing superior metabolic activity, cytoskeletal organization, collagen expression, and matrix mineralization. Surface cationic charge density and controlled borate ion flux are identified as coupled regulators of antibacterial and osteogenic responses, establishing a rational drug-free framework for multifunctional implant surface engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.